Other Viruses Citation List:

October 28 - November 10, 2011

Hepatitis C virus

1. Thiazolides as Novel Antiviral Agents: II. Inhibition of Hepatitis C Virus Replication. Stachulski, A.V., C. Pidathala, E.C. Row, R. Sharma, N.G. Berry, A.S. Lawrenson, S.L. Moores, M. Iqbal, J. Bentley, S.A. Allman, G. Edwards, A. Helm, J. Hellier, B.E. Korba, J.E. Semple, and J.F. Rossignol, Journal of Medicinal Chemistry, 2011. [Epub ahead of print]; PMID[22059983].

[PubMed]. OV_1028-111011.

2. Synthesis and Biological Activity of Bimorpholine and Its Carbanucleoside. Ausmees, K., A. Selyutina, K. Kutt, K. Lippur, T. Pehk, M. Lopp, E. Zusinaite, A. Merits, and T. Kanger, Nucleosides, nucleotides & nucleic acids, 2011. 30(11): p. 897-907; PMID[22060554].

[PubMed]. OV_1028-111011.

3. Inhibitory Effects of Native/Recombinant Full-Length Camel Lactoferrin and Its N/C Lobes on Hepatitis C Virus Infection of Huh7.5 Cells. Liao, Y., E. El-Fakkarany, B. Lonnerdal, and E.M. Redwan, Journal of medical microbiology, 2011. [Epub ahead of print]; PMID[22052996].

[PubMed]. OV_1028-111011.

4. Insulin-induced mTOR Activity Exhibits anti-Hepatitis C Virus Activity. Muraoka, T., T. Ichikawa, N. Taura, H. Miyaaki, S. Takeshita, M. Akiyama, S. Miuma, E. Ozawa, H. Isomoto, F. Takeshima, and K. Nakao, Molecular Medicine Reports, 2011. [Epub ahead of print]; PMID[22052332].

[PubMed]. OV_1028-111011.

5. Quinoline Tricyclic Derivatives. Design, Synthesis and Evaluation of the Antiviral Activity of Three New Classes of RNA-dependent RNA Polymerase Inhibitors. Carta, A., I. Briguglio, S. Piras, P. Corona, G. Boatto, M. Nieddu, P. Giunchedi, M.E. Marongiu, G. Giliberti, F. Iuliano, S. Blois, C. Ibba, B. Busonera, and P. La Colla, Bioorganic & Medicinal Chemistry, 2011. 19(23): p. 7070-7084; PMID[22047799].

[PubMed]. OV_1028-111011.

6. The Antiviral Protein Viperin Inhibits Hepatitis C Virus Replication via Interaction with Nonstructural Protein 5A. Helbig, K.J., N.S. Eyre, E. Yip, S. Narayana, K. Li, G. Fiches, E.M. McCartney, R.K. Jangra, S.M. Lemon, and M.R. Beard, Hepatology (Baltimore, Md.), 2011. 54(5): p. 1506-1517; PMID[22045669].

[PubMed]. OV_1028-111011.

7. Phosphorodiamidates as a Promising New Phosphate Pro-drug Motif for Antiviral Drug Discovery: Application to anti-HCV Agents. McGuigan, C., K. Madela, M. Aljarah, C. Bourdin, M. Arrica, E. Barrett, S. Jones, A. Kolykhalov, B. Bleiman, D. Bryant, B. Ganguly, E. Gorovits, G. Henson, D. Hunley, J. Hutchins, J. Muhammad, A. Obikhod, J. Patti, R. Walters, J. Wang, J. Vernachio, C. Ramamurty, S. Battina, and S.D. Chamberlain, Journal of Medicinal Chemistry, 2011. [Epub ahead of print]; PMID[22039920].

[PubMed]. OV_1028-111011.

8. Novel Platinum(II) and Palladium(II) Complexes of Thiosemicarbazones Derived from 5-Substitutedthiophene-2-carboxaldehydes and Their Antiviral and Cytotoxic Activities. Karakucuk-Iyidogan, A., D. Tasdemir, E.E. Oruc-Emre, and J. Balzarini, European Journal of Medicinal Chemistry, 2011. 46(11): p. 5616-5624; PMID[21993152].

[PubMed]. OV_1028-111011.

Citations from the ISI Web of Knowledge Listings for O.V.

9. Preclinical Characteristics of a Novel Series of Potent HCV N53/4a Protease Inhibitors with Robust Once Daily Dosing Potential. Buckman, B.O., J. Nicholas, V. Serebryany, R. Rajagopalan, K. Kossen, D. Ruhrmund, S. Misialek, L. Hooi, L. Pan, L. Huang, C. Schaefer, S. Pietranico-Cole, K. Klumpp, and S. Seiwert, Hepatology, 2011. 54: p. 550A-551A; ISI[000295578002386].

[WOS]. OV_1028-111011.

10. Ribavirin and IFN-alpha each Inhibits HCV IRES Mediated Translation and Synergistically Inhibits HCV Replication in Cells with a Functional JAK-STAT Pathway. Chandra, S., S. Hazari, P.K. Chandra, F. Gunduz, L.L. Bao, L.A. Balart, and S. Dash, Hepatology, 2011. 54: p. 798A-799A; ISI[000295578003162].

[WOS]. OV_1028-111011.

11. Metformin and Rapamycin Interact with Insulin Signalling Pathway and Inhibit HCV Replication in Vitro. Del Campo, J.A., M. Garcia-Valdecasas, M. Cuaresma, A. Rojas, and M. Romero-Gomez, Hepatology, 2011. 54: p. 1347A-1347A; ISI[000295578004563].

[WOS]. OV_1028-111011.

12. Antiviral Activity of Leaves Extracts of Marrubium alysson L. Edziri, H., M. Mastouri, M.A. Mahjoub, S. Ammar, Z. Mighri, L. Gutmann, and M. Aouni, Journal of Medicinal Plants Research, 2011. 5(3): p. 360-363; ISI[000296009200010].

[WOS]. OV_1028-111011.

13. Synergy of Entry Inhibitors and Direct Acting Antivirals or Interferon-alfa Identifies Novel Antiviral Combinations for Hepatitis C Virus Infection. Fofana, I., F. Xiao, C. Thumann, J. Lupberger, P. Leyssen, J.H. Neyts, F. Habersetzer, M. Doffoel, M.B. Zeisel, and T.F. Baumert, Hepatology, 2011. 54: p. 401A-401A; ISI[000295578002084].

[WOS]. OV_1028-111011.

14. A Second Generation HCV NS3/4a Protease Inhibitor is Active against Common Resistance Associated Variants (RAVs) and Exhibits Cross-genotype Activity. Graham, D., A. Acosta, Z.Y. Guo, J.A. Howe, R.A. Ogert, M.D. Miller, D. Hazuda, D.B. Olsen, S. Ludmerer, J.M. Strizki, and R.J. Barnard, MK-5172, Hepatology, 2011. 54: p. 543A-543A; ISI[000295578002370].

[WOS]. OV_1028-111011.

15. Robust Antiviral Activity of Lambda-interferon (IL-29) against HCV in Interferon Alpha Resistant HUH-7 Cells with a Defective JAK-STAT Signaling. Hazari, S., S. Nayak, P.K. Chandra, D. Kaushal, L.A. Balart, and S. Dash, Hepatology, 2011. 54: p. 793A-793A; ISI[000295578003151].

[WOS]. OV_1028-111011.

16. Protoporphyrin, a Novel Endogenous HCV NS3-4a Protease Inhibitor, Displays Anti-viral Activity. Hou, W.H., Q. Tian, L.W. Schrum, and H.L. Bonkovsky, ZINC Hepatology, 2011. 54: p. 794A-794A; ISI[000295578003153].

[WOS]. OV_1028-111011.

17. Antiviral Effect of a Novel Interferon-inducible Protein, IFI-27, against Hepatitis C Virus Replication. Itsui, Y., N. Sakamoto, G. Suda, M. Nakagawa, S. Kakinuma, S. Azuma, T. Yauchi, and M. Watanabe, Hepatology, 2011. 54: p. 1338A-1338A; ISI[000295578004546].

[WOS]. OV_1028-111011.

18. Nitazoxanide Exhibits Synergy with HCV Protease Inhibitors and Prevents the Emergence of Telaprevir-resistant HCV Mutants in Combination Treatments in Cell Culture. Korba, B., K.E. Farrar, and C. Yon, Hepatology, 2011. 54: p. 546A-546A; ISI[000295578002377].

[WOS]. OV_1028-111011.

19. Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV Inhibitors. Lazerwith, S.E., G. Bahador, E. Canales, G.F. Cheng, L. Chong, M.O. Clarke, E. Doerffler, E.J. Eisenberg, J. Hayes, B. Lu, Q. Liu, M. Matles, M. Mertzman, M.L. Mitchell, P. Morganelli, B.P. Murray, M. Robinson, R.G. Strickley, M. Tessler, N. Tirunagari, J.H. Wang, Y.J. Wang, J.R. Zhang, X.B. Zheng, W.D. Zhong, and W.J. Watkins, ACS Medicinal Chemistry Letters, 2011. 2(10): p. 715-719; ISI[000295915200001].

[WOS]. OV_1028-111011.

20. Human safety, Pharmacokinetics and Antiviral Activity of TMC647055, a Novel HCV Non-nucleoside Polymerase Inhibitor. Leempoels, J., H.W. Reesink, S. Bourgeois, L. Vijgen, M.C. Rouan, G. Ispas, K. Marien, P. Van Remoortere, G.C. Fanning, K. Simmen, and R. Verloes, Hepatology, 2011. 54: p. 533A-533A; ISI[000295578002350].

[WOS]. OV_1028-111011.

21. 25-Hydroxyvitamin D Inhibits Hepatitis C Virus Replication and Production of the Infectious Viruses. Matsumura, T., T. Kato, M. Tasaka-Fujita, A. Murayama, T. Masaki, T. Wakita, and M. Imawari, Hepatology, 2011. 54: p. 547A-547A; ISI[000295578002379].

[WOS]. OV_1028-111011.

22. Synthesis and Antiviral Evaluation of alpha-L-2 '-Deoxythreofuranosyl Nucleosides. Toti, K.S., M. Derudas, C. McGuigan, J. Balzarini, and S. Van Calenbergh, European journal of medicinal chemistry, 2011. 46(9): p. 3704-3713; ISI[000295237400018].

[WOS]. OV_1028-111011.

23. Reduction of HCV Replication by HMG-CoA-Reductase Inhibitors via KLF2-dependent Induction of Heme Oxygenase 1. Wustenberg, A., A.D. Keller, E. Lehmann, H. Sirma, R. Bartenschlager, V. Lohmann, C. Loscher, M. Dandri, G. Tiegs, and G. Sass, Hepatology, 2011. 54: p. 399A-400A; ISI[000295578002081].

[WOS]. OV_1028-111011.

24. E2112 is a Novel Oxidosqualene cyclase Inhibitor Exhibiting anti-HCV Activity in Genotype 1b subgenome Replicon Cells. Yanagimachi, M., M. Ino, M. Uesugi, Y. Sato, F. Bernier, K. Miyazaki, S.I. Agoulnik, J. Simon, K. Aoshima, and Y. Oda, Hepatology, 2011. 54: p. 549A-549A; ISI[000295578002382].

[WOS]. OV_1028-111011.

25. Novel Hepatitis C Virus NS5a Inhibitors with Improved Potency against Genotype-1a Replicons and Replicons Carrying Mutations Associated with Viral Resistance to 1st Generation NS5a Inhibitors. Yang, G.W., Y.S. Zhao, D. Patel, J.L. Fabrycki, C. Marlor, J. Rivera, K. Stauber, J. Wiles, V. Gadhachanda, A. Hashimoto, D.W. Chen, Q.P. Wang, G. Pais, X.Z. Wang, M. Deshpande, A. Phadke, and M.J. Huang, Hepatology, 2011. 54: p. 537A-537A; ISI[000295578002357].

[WOS]. OV_1028-111011.

26. In Vitro Selection of Resistance to GS-9451, a Novel and Potent Inhibitor of HCV NS3 Protease. Yang, H.L., T.C. Appleby, X.W. Chen, and W.E. Delaney, Hepatology, 2011. 54: p. 1352A-1352A; ISI[000295578004574].

[WOS]. OV_1028-111011.

27. Synthesis and Antiviral Activity of (E)-3-(4-or 6-Methylbenzo d thiazol-2-yl-amino)-2-cyano-3-(methylthio)acrylate Derivatives. Zhang, H., X.Y. Li, D.Y. Hu, S. Yang, H.T. Fan, X. Wei, and B.A. Song, Chinese Journal of Organic Chemistry, 2011. 31(9): p. 1419-1424; ISI[000295758400010].

[WOS]. OV_1028-111011.